Medical Devices: A Pilot Program to Evaluate a Proposed Globally Harmonized Alternative for Premarket Procedures; Guidance for Industry and FDA Staff; Availability, 68465-68466 [05-22387]

Download as PDF Federal Register / Vol. 70, No. 217 / Thursday, November 10, 2005 / Notices • Any unusual condition, such as a high fever or behavior changes. Signs of a serious allergic reaction can include difficulty breathing, hoarseness or wheezing, hives, paleness, weakness, a fast heart beat or dizziness. What should I do? • Call a doctor, or get the person to a doctor right away. • Tell your doctor what happened, the date and time it happened, and when the vaccination was given. • Ask your doctor, nurse, or health department to report the reaction by filing a Vaccine Adverse Event Reporting System (VAERS) form. Or you can file this report through the VAERS Web site at https:// www.vaers.hhs.gov, or by calling 1–800– 822–7967. VAERS does not provide medical advice. 8. The National Vaccine Injury Compensation Program In the event that you or your child has a serious reaction to a vaccine, a Federal program has been created to help pay for the care of those who have been harmed. For details about the National Vaccine Injury Compensation Program, call 1– 800–338–2382 or visit their Web site at https://www.hrsa.gov/osp/vicp. 9. How can I learn more? • Ask your immunization provider. They can give you the vaccine package insert or suggest other sources of information. • Call your local or state health department. • Contact the Centers for Disease Control and Prevention (CDC): —Call 1–800–232–4636 (1–800–CDC– INFO). —Visit CDC’s Web site at https:// www.cdc.gov/flu. —Vaccine Information Statement. —Live, Attenuated Influenza Vaccine. (October 20, 2005) 42 U.S.C. 300aa–26. Department of Health and Human Services, Centers for Disease Control and Prevention, National Immunization Program. Dated: November 4, 2005. James D. Seligman, Associate Director for Program Services, Centers for Disease Control and Prevention. [FR Doc. 05–22441 Filed 11–9–05; 8:45 am] BILLING CODE 4163–18–P VerDate Aug<31>2005 19:02 Nov 09, 2005 Jkt 208001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2001D–0281] Medical Devices: A Pilot Program to Evaluate a Proposed Globally Harmonized Alternative for Premarket Procedures; Guidance for Industry and FDA Staff; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled ‘‘A Pilot Program to Evaluate a Proposed Globally Harmonized Alternative for Premarket Procedures; Guidance for Industry and FDA Staff.’’ The revised guidance extends the voluntary pilot premarket review program Summary Technical Documentation (STED pilot) until we have received an adequate number of submissions to evaluate the STED pilot. The pilot program is intended for evaluating the utility of an alternative submission procedure. DATES: Submit written or electronic comments on the guidance at any time. Submit written requests for single copies on a 3.5’’ diskette of the guidance document entitled ‘‘A Pilot Program to Evaluate a Proposed Globally Harmonized Alternative for Premarket Procedures; Guidance for Industry and FDA Staff’’ to the Division of Small Manufacturers, International, and Consumer Assistance (HFZ–220), Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send one self-addressed adhesive label to assist that office in processing your request, or fax your request to 301–443– 8818. See SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance. Submit written comments concerning this guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to https:// www.fda.gov/dockets/ecomments. Identify comments with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Harry R. Sauberman, Center for Devices and Radiological Health (HFZ–480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–4879, or Kenneth J. Cavanaugh Jr., Center for Devices and Radiological ADDRESSES: PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 68465 Health (HFZ–450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–8517. SUPPLEMENTARY INFORMATION: I. Background In the Federal Register of June 26, 2003 (68 FR 38068), FDA announced the availability of a guidance document entitled ‘‘A Pilot Program to Evaluate a Proposed Globally Harmonized Alternative for Premarket Procedures; Guidance for Industry and FDA Staff.’’ The guidance document announced a pilot program for a premarket review program and encouraged participation from the medical device industry. The pilot program is intended to evaluate the utility of an alternative submission procedure as described in the draft STED document prepared by Study Group 1 of the Global Harmonization Task Force (GHTF). The document seeks to harmonize the different requirements for premarket submissions in various countries. The June 26, 2003, guidance and notice of availability announced that the pilot program would be in effect for 1 year from the date of publication of the notice of availability. In the Federal Register of July 23, 2004 (69 FR 44040), the pilot program was subsequently extended until June 25, 2005. FDA has received no comments on the guidance issued on June 26, 2003, or the updated version published on July 23, 2004. In this revised guidance, FDA is extending the pilot program until we have received a sufficient number of submissions to evaluate the pilot program. In addition, FDA is updating the contact information and the references to the GHTF documents, along with other minor editorial changes. The FDA guidance document is intended to assist the medical device industry in making submissions to FDA that use a proposed internationally harmonized format and content for premarket submissions, e.g., premarket approval applications and 510(k) submissions in the United States. The revised guidance is a level 2 guidance under FDA’s good guidance practices (GGPs) regulation (21 CFR 10.115). FDA made the guidance available on its Web site at https://www.fda.gov/cdrh/ode/ guidance/1347.html. The GHTF is a voluntary group comprised of medical device regulatory officials and industry representatives from the United States, Canada, Australia, the European Union, and Japan. The goals of the GHTF include the following items: (1) Encourage convergence in regulatory practices with respect to ensuring the safety, effectiveness, performance, and quality E:\FR\FM\10NON1.SGM 10NON1 68466 Federal Register / Vol. 70, No. 217 / Thursday, November 10, 2005 / Notices of medical devices; (2) promote technological innovation; and (3) facilitate international trade. GHTF provides further information concerning the structure, goals, and procedures at the GHTF Web site and can be accessed at https://ghtf.org. II. Significance of Guidance This guidance is being issued consistent with FDA’s Good Guidance Practice (GGP) regulation (21 CFR 10.115). The guidance represents the agency’s current thinking on the GHTF recommendations as related to premarket submission to FDA. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute and regulations. III. Electronic Access To receive a copy of ‘‘A Pilot Program to Evaluate a Proposed Globally Harmonized Alternative for Premarket Procedures; Guidance for Industry and FDA Staff,’’ by fax call CDRH Facts-OnDemand system at 800–899–0381 or 301–827–0111 from a touch-tone telephone. Press 1 to enter the system. At the second voice prompt press 1 to order a document. Enter the document number (1347) followed by the pound sign #. Follow the remaining voice prompts to complete your request. To receive ‘‘A Pilot Program to Evaluate a Proposed Globally Harmonised Alternative for Premarket Procedures; Guidance for Industry and FDA Staff,’’ you may either send a fax request to 301–443–8818 to receive a hard copy of the document, or send an e-mail request to gwa@cdrh.fda.gov to receive a hard copy or an electronic copy. Please use the document number 1347 to identify the guidance you are requesting. Persons interested in obtaining a copy of the guidance may also do so by using the Internet. CDRH maintains an entry on the Internet for easy access to information including text, graphics, and files that may be downloaded to a personal computer with Internet access. Updated on a regular basis, the CDRH home page includes: Device safety alerts, Federal Register reprints, information on premarket submissions (including lists of approved applications and manufacturers’ addresses), small manufacturer’s, information on video conferencing, and electronic submissions, Mammography Matters, and other device-related information. The CDRH web site home page may be accessed at https://www.fda.gov/cdrh. A search capability for all CDRH guidance VerDate Aug<31>2005 19:02 Nov 09, 2005 Jkt 208001 documents is available at https:// www.fda.gov/cdrh/guidance.html. Guidance documents are also available on the Division of Dockets Management Internet site at https://www.fda.gov/ ohrms/dockets. IV. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments received may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: November 2, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 05–22387 Filed 11–9–05; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of Inspector General Program Exclusions: October 2005 AGENCY: Office of Inspector General, HHS. ACTION: Notice of program exclusions. During the month of October 2005, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and nonprocurement programs and activities. PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 Subject name/address Effective date PROGRAM-RELATED CONVICTIONS ADAIR, KARISTA ..................... LEWISBURG, TN AUSTIN, HOWARD .................. OAKDALE, LA BAILEY, LAWRENCE ............... SHREVEPORT, LA BESAW NALEN, KIMBERLY ... MANCHESTER, NH BLACK, ANTONIA .................... FLINT, TX CONVENIENT DENTAL CARE CENTER, PC ........................ OKEMOS, MI DE LA CRUZ, ALFONSO ......... LOS ANGELES, CA ERLICH, RUSSELL .................. BROOKLYN, NY FLORES, SILVIA ...................... ONTARIO, CA GARCIA, ROSEMARIE ............ SAN DIEGO, CA HAMILTON BENNETT, MAISHA ................................ CHICAGO, IL HAWKINS, KIMBERLY ............. SHAKOPEE, MN HERNANDEZ, KAREN ............. OKLAHOMA CITY, OK KATZ, RONALD ....................... OTISVILLE, NY KEMMETT, BARBARA ............. BRIDGEWATER, MA KUBRICKY, MARK ................... OGDEN, UT LAKHTER, ALEXANDER ......... E STROUDSBURG, PA LEBEL, ALEXANDER ............... BROOKLYN, NY LEEDS, LORI ........................... SHAKOPEE, MN LITTLE, MARK ......................... ANTHONY, TX MALVAREZ, NORBERTO ........ MIAMI, FL MARTINEZ, CESAR ................. MIAMI, FL MORAN, PAT ........................... WICHITA FALLS, TX SHUMATE, TAMMY ................. LOUISVILLE, KY UTUK, BECALO ....................... BRYAN, TX VU, PHOUA .............................. SAN DIEGO, CA WALLACE, SHIRLEY ............... JONESBORO, AR WILLIAMS-WRIGHT, MYRA .... MIAMI, FL 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 11/20/2005 FELONY CONVICTION FOR HEALTH CARE FRAUD CHAVEZ, WILLIAM .................. MIAMI, FL GONZALEZ, DUVIEL ............... MIAMI, FL GORRIN, EDDY ....................... MIAMI, FL KRZYS, PENNY ....................... E:\FR\FM\10NON1.SGM 10NON1 11/20/2005 11/20/2005 11/20/2005 11/20/2005

Agencies

[Federal Register Volume 70, Number 217 (Thursday, November 10, 2005)]
[Notices]
[Pages 68465-68466]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-22387]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2001D-0281]


Medical Devices: A Pilot Program to Evaluate a Proposed Globally 
Harmonized Alternative for Premarket Procedures; Guidance for Industry 
and FDA Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
availability of a guidance entitled ``A Pilot Program to Evaluate a 
Proposed Globally Harmonized Alternative for Premarket Procedures; 
Guidance for Industry and FDA Staff.'' The revised guidance extends the 
voluntary pilot premarket review program Summary Technical 
Documentation (STED pilot) until we have received an adequate number of 
submissions to evaluate the STED pilot. The pilot program is intended 
for evaluating the utility of an alternative submission procedure.

DATES: Submit written or electronic comments on the guidance at any 
time.

ADDRESSES: Submit written requests for single copies on a 3.5'' 
diskette of the guidance document entitled ``A Pilot Program to 
Evaluate a Proposed Globally Harmonized Alternative for Premarket 
Procedures; Guidance for Industry and FDA Staff'' to the Division of 
Small Manufacturers, International, and Consumer Assistance (HFZ-220), 
Center for Devices and Radiological Health, Food and Drug 
Administration, 1350 Piccard Dr., Rockville, MD 20850. Send one self-
addressed adhesive label to assist that office in processing your 
request, or fax your request to 301-443-8818. See SUPPLEMENTARY 
INFORMATION section for information on electronic access to the 
guidance.
    Submit written comments concerning this guidance to the Division of 
Dockets Management (HFA-305), Food and Drug Administration, 5630 
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments 
to https://www.fda.gov/dockets/ecomments. Identify comments with the 
docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Harry R. Sauberman, Center for Devices 
and Radiological Health (HFZ-480), Food and Drug Administration, 9200 
Corporate Blvd., Rockville, MD 20850, 301-443-4879, or Kenneth J. 
Cavanaugh Jr., Center for Devices and Radiological Health (HFZ-450), 
Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 
20850, 301-443-8517.

SUPPLEMENTARY INFORMATION:

I. Background

    In the Federal Register of June 26, 2003 (68 FR 38068), FDA 
announced the availability of a guidance document entitled ``A Pilot 
Program to Evaluate a Proposed Globally Harmonized Alternative for 
Premarket Procedures; Guidance for Industry and FDA Staff.'' The 
guidance document announced a pilot program for a premarket review 
program and encouraged participation from the medical device industry. 
The pilot program is intended to evaluate the utility of an alternative 
submission procedure as described in the draft STED document prepared 
by Study Group 1 of the Global Harmonization Task Force (GHTF). The 
document seeks to harmonize the different requirements for premarket 
submissions in various countries.
    The June 26, 2003, guidance and notice of availability announced 
that the pilot program would be in effect for 1 year from the date of 
publication of the notice of availability. In the Federal Register of 
July 23, 2004 (69 FR 44040), the pilot program was subsequently 
extended until June 25, 2005. FDA has received no comments on the 
guidance issued on June 26, 2003, or the updated version published on 
July 23, 2004. In this revised guidance, FDA is extending the pilot 
program until we have received a sufficient number of submissions to 
evaluate the pilot program. In addition, FDA is updating the contact 
information and the references to the GHTF documents, along with other 
minor editorial changes. The FDA guidance document is intended to 
assist the medical device industry in making submissions to FDA that 
use a proposed internationally harmonized format and content for 
premarket submissions, e.g., premarket approval applications and 510(k) 
submissions in the United States. The revised guidance is a level 2 
guidance under FDA's good guidance practices (GGPs) regulation (21 CFR 
10.115). FDA made the guidance available on its Web site at https://
www.fda.gov/cdrh/ode/guidance/1347.html.
    The GHTF is a voluntary group comprised of medical device 
regulatory officials and industry representatives from the United 
States, Canada, Australia, the European Union, and Japan. The goals of 
the GHTF include the following items: (1) Encourage convergence in 
regulatory practices with respect to ensuring the safety, 
effectiveness, performance, and quality

[[Page 68466]]

of medical devices; (2) promote technological innovation; and (3) 
facilitate international trade. GHTF provides further information 
concerning the structure, goals, and procedures at the GHTF Web site 
and can be accessed at https://ghtf.org.

II. Significance of Guidance

    This guidance is being issued consistent with FDA's Good Guidance 
Practice (GGP) regulation (21 CFR 10.115). The guidance represents the 
agency's current thinking on the GHTF recommendations as related to 
premarket submission to FDA. It does not create or confer any rights 
for or on any person and does not operate to bind FDA or the public. An 
alternative approach may be used if such approach satisfies the 
requirements of the applicable statute and regulations.

III. Electronic Access

    To receive a copy of ``A Pilot Program to Evaluate a Proposed 
Globally Harmonized Alternative for Premarket Procedures; Guidance for 
Industry and FDA Staff,'' by fax call CDRH Facts-On-Demand system at 
800-899-0381 or 301-827-0111 from a touch-tone telephone. Press 1 to 
enter the system. At the second voice prompt press 1 to order a 
document. Enter the document number (1347) followed by the pound sign 
. Follow the remaining voice prompts to complete your request.
    To receive ``A Pilot Program to Evaluate a Proposed Globally 
Harmonised Alternative for Premarket Procedures; Guidance for Industry 
and FDA Staff,'' you may either send a fax request to 301-443-8818 to 
receive a hard copy of the document, or send an e-mail request to 
gwa@cdrh.fda.gov to receive a hard copy or an electronic copy. Please 
use the document number 1347 to identify the guidance you are 
requesting.
    Persons interested in obtaining a copy of the guidance may also do 
so by using the Internet. CDRH maintains an entry on the Internet for 
easy access to information including text, graphics, and files that may 
be downloaded to a personal computer with Internet access. Updated on a 
regular basis, the CDRH home page includes: Device safety alerts, 
Federal Register reprints, information on premarket submissions 
(including lists of approved applications and manufacturers' 
addresses), small manufacturer's, information on video conferencing, 
and electronic submissions, Mammography Matters, and other device-
related information. The CDRH web site home page may be accessed at 
https://www.fda.gov/cdrh. A search capability for all CDRH guidance 
documents is available at https://www.fda.gov/cdrh/guidance.html. 
Guidance documents are also available on the Division of Dockets 
Management Internet site at https://www.fda.gov/ohrms/dockets.

IV. Comments

    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) written or electronic comments regarding this document. 
Submit a single copy of electronic comments or two paper copies of any 
mailed comments, except that individuals may submit one copy. Comments 
are to be identified with the docket number found in brackets in the 
heading of this document. Comments received may be seen in the Division 
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: November 2, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-22387 Filed 11-9-05; 8:45 am]
BILLING CODE 4160-01-S
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.